IP Library Patent Application 11640107
Patent Application
App. No. 11/640,107

Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/640,107
Abstract

The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment humans for pain and/or inflammation while reducing gastrointestinal side effects.

Claims (29)

1 . An enteric coated capsule comprising a non-steroidal anti-inflammatory drug and an acid inhibitor.

2 . The enteric coated capsule of claim 1 , wherein said enteric coating is selected from methacrylic acid copolymers, hydroxopropyl methylcellulose phthalate, cellulose acetate phthalate and combinations thereof.

3 . The enteric coated capsule of claim 1 , wherein the amount of non-steroidal anti-inflammatory drug is between 1 mg and 500 mg.

4 . The enteric coated capsule of claim 1 , wherein the non-steroidal anti-inflammatory drug is meloxicam.

5 . The enteric coated capsule of claim 4 , wherein the meloxicam is at an amount between 1 mg and 50 mg.

6 . The enteric coated capsule of claim 1 , wherein the acid inhibitor is a proton pump inhibitor.

7 . The enteric coated capsule of claim 6 , wherein the amount of proton pump inhibitor is between 1 mg and 500 mg.

8 . The enteric coated capsule of claim 7 , wherein the acid inhibitor is omeprazole.

9 . The enteric coated capsule of claim 8 , wherein the wherein the omeprazole is at an amount between 1 mg and 100 mg.

10 . A pharmaceutical composition comprising a non-steroidal anti-inflammatory drug and a reversible proton pump inhibitor.

11 . The pharmaceutical composition of claim 10 in which said inhibitors is not enteric coated.

12 . An orally dissolvable film comprising a combination of pharmaceutically active agents, wherein said agents are a non-steroidal anti-inflammatory drug and an acid inhibitor.

13 . The film of claim 12 , wherein the amount of non-steroidal anti-inflammatory drug is between 1 mg and 100 mg.

14 . The film of claim 12 , wherein the non-steroidal anti-inflammatory drug is meloxicam.

15 . The film of claim 12 , wherein the acid inhibitor is enteric coated.

16 . The film of claim 12 , wherein the acid inhibitor is not enteric coated.

17 . The film of claim 12 , wherein the acid inhibitor is a proton pump inhibitor.

18 . The film of claim 17 , wherein the amount of proton pump inhibitor is at an amount between 1 mg and 100 mg.

19 . The film of claim 17 , wherein the wherein the proton pump inhibitor is omeprazole.

20 . The film of claim 19 , wherein omeprazole is enteric coated.

21 . The film of claim 20 , wherein the wherein the omeprazole is at an amount between 1 mg and 100 mg.

22 . The film of claim 12 , wherein the acid inhibitor is an H 2 antagonist.

23 . The film of claim 22 , wherein the H 2 antagonist is at an amount between 5 mg and 50 mg.

24 . The film of claim 22 wherein the H 2 antagonist is famotidine.

25 . An orally dissolvable film comprising meloxicam and enteric coated omeprazole.

26 . A method of treating pain and/or inflammation in a patient comprising administering to said patient a composition according to claim 1 .

27 . A method of protecting the gastrointestinal tract from side effects associated with non-steroidal anti-inflammatory drug therapy in a patient comprising administering to said patient a composition according to claim 1 .

28 . A method of treating pain and/or inflammation in a patient comprising administering to said patient a composition according to claim 12 .

29 . A method of protecting the gastrointestinal tract from side effects associated with non-steroidal anti-inflammatory drug therapy in a patient comprising administering to said patient a composition according to claim 12.

Assignments (3)
CHANGE OF NAME Recorded Aug 5, 2010
From: HORIZON THERAPEUTICS, INC.
To: HORIZON PHARMA USA, INC.
Reel/Frame 024798/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2009
From: COGENTUS PHARMACEUTICALS, INC.
To: HORIZON THERAPEUTICS, INC.
Reel/Frame 023380/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2007
From: TANANBAUM, JAMES B.; VADAS, ELIZABETH; GOLDSMITH, MARK A.
To: COGENTUS PHARMACEUTICALS, INC.
Reel/Frame 019027/0926 →